§02 · Status · NDA 210557
Is PT-141 FDA-Approved? Regulatory Status
Yes, with a tight boundary. Bremelanotide is approved for one diagnosis in one population — and explicitly not for the uses people most often ask about.
The short version
Is PT-141 FDA-approved? Yes — but read the fine print before you read anything else. The active drug, bremelanotide, was approved by the FDA on June 21, 2019 under application number NDA 210557 [7][10]. The approval covers one condition in one group: acquired, generalized hypoactive sexual desire disorder (HSDD) — low sexual desire causing distress — in women who have not gone through menopause [3][10].
That is the entire approval. It does not cover men, women past menopause, erectile dysfunction, or sexual "enhancement" [1][10]. Doctors may legally prescribe a drug off-label, but "off-label" means the FDA reviewed neither the safety nor the benefit for that use. Separately, the "PT-141 research chemical" sold online is not the approved drug and sits outside this framework entirely, with no agency checking its contents [10]. The sections below lay each line out with its source.
The approved indication — the one line that is on the label
Bremelanotide's label is precise. The approved use is acquired, generalized HSDD in premenopausal women [10]. "Acquired" means the low desire developed after a period of normal desire; "generalized" means it is not limited to a particular partner or situation. The approval rests on two identical Phase 3 trials (RECONNECT) in 1,267 premenopausal women, both of which met their co-primary goals on desire and desire-related distress [3].
A review of female sexual dysfunction treatment places bremelanotide squarely in this slot — indicated for generalized acquired HSDD in premenopausal women, distinct from off-label transdermal testosterone used in postmenopausal women [8]. The approval also arrived in a notable year for peptide drugs: a survey of 2019 FDA peptide and oligonucleotide approvals situates bremelanotide within that wider trend [9].
PT-141 for men
PT-141 is not FDA-approved for men. This is a frequent point of confusion, so it is worth stating plainly. Early-development studies did test the compound in men: systemic administration produced rapid, dose-dependent erectile activity in men with erectile dysfunction, consistent with a central mechanism [1]. A review of centrally acting agents for male sexual dysfunction describes bremelanotide as a candidate among the first such agents with potential clinical utility [13], and preclinical work supports a CNS-mediated erection effect in animal models [15].
But none of that produced an approval for men. The drug's only approved indication is HSDD in premenopausal women [10]. Any use in men is off-label and outside the data the FDA reviewed.
PT-141 for women
PT-141 for women is approved — but only for a specific group of women. The approval covers premenopausal women with acquired, generalized HSDD [10]. It was not approved for postmenopausal women; the treatment review notes transdermal testosterone is what is used off-label in that population, not bremelanotide [8].
The female-specific evidence is the strongest part of the record. Beyond the two RECONNECT trials [3], a 52-week open-label extension in 684 women showed sustained desire improvements and no new safety signals [4], and a neuroimaging study in 31 premenopausal women with HSDD found MC4R activation raised desire for up to 24 hours and changed brain processing of erotic cues [5]. The preclinical groundwork was laid in female rats, where PT-141 selectively increased solicitational (desire-driven) behavior [2].
Legal status and the research-chemical boundary
There are two different things wearing the same name, and the legal picture depends entirely on which one you mean. Bremelanotide is a prescription pharmaceutical for its approved HSDD indication [7]. The "PT-141 research chemical" is material sold for laboratory use only; it is not the approved drug and is not for human consumption [10].
That distinction is the heart of due diligence. The approved drug went through manufacturing controls, a reviewed label, and post-approval safety monitoring. The research-chemical form has none of that — no regulatory oversight of identity, purity, or concentration [10]. On the anti-doping side, melanocortin agonists fall under WADA's framework for non-approved substances; athletes should consult current WADA guidance directly [10].